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 The International Collaboration on Cancer Reporting
was established to internationally unify and standardize
the pathologic reporting of cancers based on collected
evidence, as well as to allow systematic multi-institutional
intercountry data collection to guide cancer care in the
future. This data set has been developed by the collabo-
rative efforts of an international multidisciplinary panel of
experts involved in the care of patients with carcinomas of
the nasal cavity and paranasal sinuses (sinonasal tract). The
nasal cavity and paranasal sinuses (including frontal,
sphenoid, ethmoid, and maxillary sinuses) comprise a very
complex anatomic area of the head and neck, affected by a
sometimes bewildering array of neoplasms. Management
of malignancies in this anatomic region involves complex
surgery because of the anatomic confines and close
proximity to many vital structures. Given a multidisciplin-
ary approach, the standardized reporting of the carcino-
mas that develop in this anatomic region include both
required (core) and recommended (noncore) elements in
pathology reporting in order to be able to identify critical
prognostic factors, often requiring clinical and radiologic
correlation. A summary of the International Collaboration
on Cancer Reporting guidelines and clinically relevant
elements, along with additional explanatory notes, are
provided, based on evidentiary support from the literature,
set in the context of practical application.
(Arch Pathol Lab Med. 2019;143:424–431; doi:
10.5858/arpa.2018-0404-SA)
S inonasal malignancies are rare and aggressive tumors,with an incidence of less than 1 case per 100 000
population annually, representing 3% to 5% of all head and
neck cancers.1–3 They occur predominately in adult male
patients and present with nonspecific symptoms that are
often indistinguishable from inflammatory diseases. Thus,
the diagnosis is often delayed with the tumor in locally
advanced stage. In comparison with other malignancies of
the head and neck, an elevated fraction of sinonasal
carcinomas can be attributed to occupational exposures,
including wood and leather dusts for intestinal-type
adenocarcinoma or to several chemical substances (glues,
formaldehyde, chrome, nickel, and compounds used in the
textile industry) for squamous cell carcinoma. Sinonasal
neuroendocrine carcinoma may also arise in the setting of
previous high-dose radiotherapy. Finally, human papillo-
mavirus (HPV) is emerging as an important etiologic factor
in a subset of sinonasal carcinomas.
A comprehensive pathologic report is essential for cancer
diagnosis, staging, prognostication, and optimal therapeutic
decision making. Moreover, standardized procedures enable
reliable data collection, cohort stratification, and research,
especially in rare cancers.
To these aims, a standardized data set ensures that
histopathology reports include all relevant information and
present it in a concise and consistent format that conforms
to international standards. The International Collaboration
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on Cancer Reporting (ICCR) was established in 2011
through a collaboration between the College of American
Pathologists, the Canadian Association of Pathologists-
Association Canadienne des Pathologists in association with
the Canadian Partnership Against Cancer, the Royal
Colleges of Pathologists of Australasia and the United
Kingdom, joined in 2013 by the European Society of
Pathologists, and followed by the American Society of
Clinical Pathology and the Royal College of Physicians of
Ireland, Faculty of Pathology, as sustaining members.
Furthermore, for this data set, members of the authoring
panel were chosen from the additional sponsoring organi-
zations: the North American Society of Head and Neck
Pathology; the American Academy of Oral and Maxillofacial
Pathology; the British Society for Oral and Maxillofacial
Pathology; and the International Association of Oral and
Maxillofacial Pathologists. The ICCR aims to produce
globally standardized, evidence-based reporting data sets
for various organ systems by harnessing international
experience and expertise.
The sinonasal tract has a very complex anatomy, with
numerous vital structures housed within a relatively
confined and limited space. Familiarity with the anatomy,
in addition to the diagnoses of the neoplasms of this region,
are important for staging and prognostic purposes. Thus, the
international collaborative effort achieved by the ICCR is
critical for the reporting of carcinomas of the sinonasal tract
to ensure international uniformity in pathologic examina-
tion and to facilitate multi-institutional and cross-regional
data collection for improved patient management. The ICCR
data sets include core and noncore elements. The core
elements are required, considered essential for the clinical
management and prognosis or staging of the neoplasms.
The noncore elements are recommended as good clinical
practice but may not be clinically validated or used in
management decisions at this time. The ICCR data set
includes the minimum reporting requirements for the
reporting of resection and biopsy specimens of mucosal
epithelial malignancies of the nasal cavities and paranasal
sinuses.69 There is significant variation in the strength of the
evidence available for these tumors, with most data derived
from retrospective case series because of the rare nature of
primary neoplasms. Sinonasal melanomas, sarcomas, and
hematolymphoid tumors are excluded. Further, this process
was conducted to incorporate the fourth series of the World
Health Organization (WHO) Classification of Head and Neck
Tumours and the 8th edition of the Union for International
Cancer Control cancer staging system.4
DATA SET ELEMENTS
Core (Required) Elements
Neoadjuvant Therapy.—Patients with locally advanced
sinonasal carcinomas may be treated with preoperative
chemotherapy or concurrent chemoradiotherapy protocols
that may result in a significant improvement in survival in
selected patients.5–9 Such treatments may significantly alter
the gross and microscopic appearance of the tumor and
result in difficulties in tumor typing and grading. Although
quantification of the extent of response is currently
considered not relevant for clinical purposes, specimens
should be extensively sampled, and changes presumably
induced by treatment should be reported. Type of (chemo)
therapy, number of cycles, interval between last cycle of
chemotherapy, and local regional treatment initiation can
also be annotated if available.
Operative Procedure.—Different options are currently
available for the surgical treatment of sinonasal malignan-
cies, which may be chosen according to histopathology,
extent of the lesion, and experience of the surgeon. Surgical
approaches include craniofacial resections (open or endo-
scopic), endoscopic endonasal resections, and combined
approaches.10–12 This results in a wide range of surgical
specimens submitted for histopathologic analysis (Figure 1).
Specimens Submitted.—Specimens from endoscopic
surgery typically consist of fragmented material that should
be properly labeled at the time of surgery, including a
description of the anatomic site and type of tissue submitted
(tumor, margin, or other). Because of the inherent
orientation difficulty in samples, separately submitted
margins, properly identified and labeled, are encouraged.
Surgical resection specimens consist most often of the
maxillary bone and adjacent anatomic structures removed
according to the extent of the primary tumor (Figure 2).13
Tumor Site.—The sinonasal tract consists of the nasal
cavity and the paired paranasal sinuses (maxillary, ethmoid,
frontal, and sphenoid). The nasal cavity can be further
subdivided into the nasal septum, floor, lateral wall, and
vestibule. Among sinonasal tract carcinomas, the most
common site of tumor origin is the maxillary sinus, followed
by the nasal cavity and ethmoid sinus. It is rare for
carcinomas to arise from the frontal or sphenoid sinuses.14–18
The precise tumor site within the sinonasal tract is
important to record. This is not always easy to determine,
because some exophytic tumors may almost entirely fill the
nasal fossa without any infiltration, and only involve a
relatively limited portion of the mucosa (Figure 3). Second,
there is prognostic importance to the tumor location. For
example, carcinomas primary to the nasal cavity have been
shown to have an improved prognosis compared with
carcinomas primary to the paranasal sinuses, likely because
nasal carcinomas give rise to symptoms (eg, nasal obstruc-
tion or epistaxis) and reach clinical attention earlier in the
disease course. Among maxillary sinus carcinomas, those
arising from the anterior-inferior portion have a better
prognosis than those arising from the superior-posterior
portion, likely because the latter group more easily involves
the skull base and/or orbit.19,20 Interestingly, primary
maxillary carcinomas have a behavior different from
carcinomas originating in the oral cavity and secondarily
involving the maxilla. Further, there are separate staging
systems for the 2 major anatomic sites: maxillary sinus and
nasal cavity and/or ethmoid sinus.4 Finally, certain carcino-
mas are closely associated with specific sinonasal subsites.
For example, intestinal-type adenocarcinomas and neuro-
endocrine carcinomas occur most often in the ethmoid
sinuses, whereas squamous cell carcinoma occurs most
often in the maxillary sinuses.21–23
It is recognized that some carcinomas, particularly highly
aggressive types like sinonasal undifferentiated carcinoma
or nuclear protein in testis (NUT) carcinoma, usually affect
more than 1 subsite. In this case, every affected site should
be specified in the report.
Tumor Dimensions.—The maximum diameter of the
tumor should ideally be assessed on the unfixed specimen to
avoid size underestimation resulting from formalin fixation–
induced shrinkage. Care should be taken not to overesti-
mate tumor size by including areas of adjacent nonneo-
plastic tissue. The gross assessment of tumor size should be
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confirmed microscopically, and in cases where nonneoplas-
tic tissue has been mistakenly incorporated into the tumor
measurement, tumor size should be adjusted accordingly. If
tumor dimensions are estimated only microscopically, then
‘‘at least’’ should be added to indicate that the measurement
is an underestimation resulting from fixation and tissue
processing. The option ‘‘cannot be assessed’’ may be used
when the tumor is submitted in fragments, as in endoscopic
resections. In these cases, radiographic imaging may also be
considered to determine tumor dimensions.
Histologic Tumor Type.—All sinonasal tract carcinomas
should be given a type based on the most recent edition of
the WHO’s Classification of Head and Neck Tumours,24
currently from the 4th edition (Table 1). Importantly,
because of an effort to reduce duplication and only including
an entity once in the book, not every histologic sinonasal
tract tumor is described.
The sinonasal tract gives rise to a very large and diverse
group of carcinomas, which may arise from the surface
epithelium or the underlying seromucinous glands. Squa-
mous cell carcinoma is, by far, the most common sinonasal
malignancy, and it is subdivided primarily into keratinizing
and nonkeratinizing subtypes (Figure 4, A). Additional
subtypes (eg, spindle cell, basaloid, adenosquamous) are
rare but should be noted if present. Uncommon carcinoma
variants (such as sinonasal undifferentiated carcinoma, NUT
carcinoma) are also included, whereas adenocarcinomas are
separated into salivary gland types, intestinal types (Figure
5), and nonintestinal types, among other less common
variants. Correct classification results in appropriate treat-
ment, correlated with overall patient outcome. These
classifications will take additional importance as targeted,
molecular-based therapies become more widespread.25–27
Histologic Tumor Grade.—A 3-tiered grading system
based on degree of differentiation is used for squamous cell
carcinoma, and it is also applied to some sinonasal
adenocarcinomas, as well as selected salivary gland neo-
plasms (eg, adenoid cystic carcinoma, mucoepidermoid
Figure 1. Resection specimens of sinonasal carcinomas. Specimen from a hemimaxillectomy (A, lateral view; B, medial view) and fragmented
material from an endoscopic procedure (inset).
Table 1. World Health Organization Classification
of Sinonasal Tract Carcinomasa
Descriptor ICD-O Codes
Keratinizing squamous cell carcinoma 8071/3
Nonkeratinizing squamous cell carcinoma 8072/3
Spindle cell squamous cell carcinoma 8074/3
Lymphoepithelial carcinoma 8082/3
Sinonasal undifferentiated carcinoma 8020/3
NUT carcinoma 8023/3
Neuroendocrine carcinomas
Small cell neuroendocrine carcinoma 8041/3




Abbreviations: ICD-O, International Classification of Diseases for
Oncology; NUT, nuclear protein in testis.
a Reproduced with permission from World Health Organization/
International Agency for Research on Cancer (IARC).24 The morphol-
ogy codes are from the ICD-O. Behavior is coded /3 for malignant
tumors.
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carcinoma, etc). Undifferentiated tumors should be consid-
ered high grade. Minor salivary gland neoplasms have
grading systems unique to selected tumors,28,29 whereas
other adenocarcinomas are assigned a grade based on
necrosis and mitotic activity.30,31 Nearly all sinonasal tract
neuroendocrine carcinomas are high grade.32
Bone/Cartilage Invasion.—Bone invasion is a frequent
finding in sinonasal carcinomas. Both bone erosion and
destruction are reported, but sometimes findings from
radiographic studies may need to be incorporated into this
evaluation because limited biopsies may not include enough
material to yield a meaningful interpretation. In resections,
it is strongly recommended that histologic sections be taken
from the areas of maximum bone involvement (after
appropriate decalcification).
Perineural Invasion.—The frequency of perineural inva-
sion (including named nerves) in sinonasal carcinomas is
lower than it is in other head and neck sites, and it varies
according to the histologic subtype, identified most fre-
quently in adenoid cystic, sinonasal undifferentiated, squa-
mous cell, and NUT carcinomas, respectively.33,34 In
sinonasal carcinomas, perineural invasion is associated with
a high rate of positive margins, with maxillary origin, and
with previous surgical treatment, but it is not an indepen-
dent prognostic factor.33
Lymphovascular Invasion.—Lymphovascular invasion
includes neoplastic cells within an endothelial-lined space,
either lymphatic or venous, and it must be distinguished
from retraction artifacts. Immunohistochemical staining for
an endothelial marker may help in this distinction in
selected cases. Lymphovascular invasion is reported in up to
60% of sinonasal squamous cell carcinomas, but its clinical
significance remains elusive.33
Margin Status.—Complete tumor resection with nega-
tive surgical margins poses a significant challenge in
sinonasal carcinomas, given the proximity to critical
anatomic structures. The presence of residual microscopic
disease has been reported with high frequency in cases
managed both by open and by endoscopic surgical
techniques.35,36 In a large series of sinonasal squamous cell
carcinomas treated with surgery, 16% had microscopic
residual disease and 13% had macroscopic positive resection
margins.37 A negative surgical margin is associated with
improved overall survival in retrospective studies for both
open and endoscopic approaches.37,38
Ideally, the resection specimen should be oriented by the
surgeon, including sutures or other annotations, best
achieved by direct communication between the surgeon
and pathologist, supplemented with specimen photography
before and after sectioning. Failing this, the margins should
be labeled by the surgeon and/or illustrated with a diagram.
Specimens from endoscopic tumor resections should also be
labeled and oriented, if possible. If the margins are sent
separately, for frozen section or otherwise, identification of
their site in relation to the resection specimen should be
clarified by the surgeon. The surgical margins—mucosal,
soft tissue, bone, and deep—should be thoroughly sampled,
because additional therapy is often predicated on margin
status. Because of limited data, a clear margin ranges from 3
to 7 mm, with 5 mm generally associated with a better
prognosis,39–43 although recurrence is seen in up to 25% of
patients with a clear margin.41,42 Depending on stage and
other factors, a narrower margin may be adequate.44,45
When the complex anatomy is taken into consideration, a
‘‘pushing’’ border into the periorbital tissues may not
Figure 2. T2-weighted magnetic resonance imaging image showing
postoperative status of a sinonasal adenocarcinoma without any
residual tumor.
Figure 3. T2-weighted magnetic resonance imaging image showing an
exophytic adenocarcinoma filling almost entirely the nasal fossa but
exclusively implanted in the olfactory area.
Arch Pathol Lab Med—Vol 143, April 2019 ICCR Sinonasal Data Set—Franchi et al 427
require orbital exenteration to achieve a 5 mm margin, if it is
a low-grade neoplasm (Figure 6). Thus, margin status is one
parameter of many used in treatment and prognostica-
tion.46–48 Most studies also consider carcinoma in situ/high-
grade dysplasia as a positive margin.40 The presence of
dysplasia at the margin is associated with a significant risk of
local recurrence49 and development of a second primary.50
Thus, this information, including distance to the margin
from invasive and in situ/dysplasia, is reported.
Pathologic Staging.—Staging of sinonasal cancer re-
mains a difficult task because of the complexity of the
anatomic site and the heterogeneity of the tumor types.
Nevertheless, an accurate staging is essential for treatment
and prognosis implications.51 The data set is based on the T
category of the 8th edition of the Union for International
Cancer Control staging system, which is identical to that of
the previous edition (Table 2). Tumors located in the
maxillary sinus are separated from those arising in the nasal
cavity and ethmoid sinus. The pT stage is based on the
involved anatomic sites, as well as invasion of the bone,
orbit, dura, and other structures. Most sinonasal carcinomas
present in advanced T category (T3 and T4). It is worth
noting that a number of studies have reported significant
discrepancies between clinical and pathological T categori-
zation.52,53 In particular, imaging is not sufficiently accurate
in the assessment of invasion of the orbit, the skull base, and
frontal or sphenoid sinuses.52 Thus, careful histopathologic
assessment is essential for a correct staging of sinonasal
carcinomas. Finally, when neck lymph node dissections are
included as part of the surgical specimen, a separate linked
data set for Nodal Excisions and Neck Dissection Specimens for
Head & Neck Tumours has to be completed.70
Noncore (Recommended) Elements
Tumor Focality.—Sinonasal carcinomas may present
with multiple synchronous lesions located in different
anatomic subsites.36 Similar to other data sets for reporting
carcinomas of the head and neck, multiple different
histologic primaries are separately reported. The term
‘‘multifocal’’ may be used for microscopic foci of in situ or
invasive carcinoma adjacent to the primary.
Coexistent Pathology.—A number of histopathologic
findings may be associated with sinonasal tract carcinomas.
The presence of squamous dysplasia/carcinoma in situ can
be used as evidence for histologic classification of the tumor.
This is especially true with spindle cell carcinoma or other
variants of squamous cell carcinoma that arise from and are
often associated with overlying squamous dysplasia/carci-
noma in situ.54
It is well recognized that a subset of sinonasal squamous
cell carcinomas, and less frequently other histologic types,
originate from preexisting sinonasal papillomas (formerly
Schneiderian papilloma). These tumors represent a group of
sinonasal carcinomas characterized by specific genetic
alterations and oncogenic mechanisms.55–57
Finally, foci of intestinal metaplasia of the adjacent
sinonasal respiratory epithelium can be detected in about
25% of intestinal-type adenocarcinomas.58,59
Ancillary Studies.—Ancillary studies are variably need-
ed for the diagnosis of specific entities at this site. For
example, NUT carcinoma is recognized by the presence of
Figure 4. Nonkeratinizing squamous cell carcinoma. The tumor consists of nonkeratinizing atypical squamoid cells, with peripheral palisading of
tumor cell nuclei (A). These tumors are frequently human papillomavirus (HPV) related, and thus positive for both p16 (B) and high-risk HPV by
DNA in situ hybridization (inset) (hematoxylin-eosin, original magnification3300 [A]; original magnifications3150 [B] and3400 [inset]).
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nuclear protein in testis (NUTM1) gene rearrangement or
positivity with the C52 monoclonal antibody against NUT
protein.60 The diagnosis of HPV-related multiphenotypic
sinonasal carcinoma requires HPV-specific testing as part of
the tumor definition (Figure 4, B),61 whereas for the
diagnosis of SMARCB1 (INI1)–deficient carcinoma, loss of
nuclear immunohistochemical staining for INI1 is re-
quired.62,63
In poorly differentiated malignancies, immunohistochem-
ical markers can be used to assign a tumor to a specific
category. Useful markers of squamous differentiation are
p40, p63, and cytokeratin 5/6, whereas markers of intestinal
differentiation, such as cytokeratin 20 and CDX2, help in the
diagnosis of intestinal-type adenocarcinoma. Neuroendo-
Figure 5. Sinonasal intestinal-type adenocarcinoma arising in a
woodworker. Histologically, the tumor is identical to a colonic
adenocarcinoma (hematoxylin-eosin, original magnification3300).
Figure 6. T2-weighted magnetic resonance imaging image showing a
sinonasal adenocarcinoma pushing but not infiltrating the orbit.
However, there is infiltration of the dura mater into the anterior cranial
fossa.
Table 2. Union for International Cancer Control
(UICC) TNM 8th Edition Pathologic Staging of Nasal
Cavity and Paranasal Sinusesa
pTx Primary tumor cannot be assessed
pT0 No evidence of primary tumor
pTis Carcinoma in situ
Maxillary sinus
pT1 Tumor limited to the mucosa with no erosion or
destruction of bone
pT2 Tumor causing bone erosion or destruction,
including extension into the hard palate and/or
middle nasal meatus, except extension to
posterior wall of maxillary sinus and pterygoid
plates
pT3 Tumor invades any of the following: bone of
posterior wall of maxillary sinus, subcutaneous
tissues, floor or medial wall of orbit, pterygoid
fossa, or ethmoid sinuses
pT4 Moderately advanced or very advanced local disease
pT4a Tumor invades any of the following: anterior orbital
contents, skin of cheek, pterygoid plates,
infratemporal fossa, cribriform plate, sphenoid or
frontal sinuses
pT4b Tumor invades any of the following: orbital apex,
dura, brain, middle cranial fossa, cranial nerves
other than maxillary division of trigeminal nerve
(V2), nasopharynx, or clivus
Nasal cavity and ethmoid sinus
pT1 Tumor restricted to one subsite of nasal cavity or
ethmoid sinus, with or without bony invasion
pT2 Tumor involves two subsites in a single site or
extends to involve an adjacent site within the
nasoethmoidal complex, with or without bony
invasion
pT3 Tumor extends to invade the medial wall or floor of
the orbit, maxillary sinus, palate, or cribriform
plate
pT4 Moderately advanced or very advanced local
disease
pT4a Tumor invades any of the following: anterior orbital
contents, skin of nose or cheek, minimal extension
to anterior cranial fossa, pterygoid plates, sphenoid
or frontal sinuses
pT4b Tumor invades any of the following: orbital apex,
dura, brain, middle cranial fossa, cranial nerves
other than V2, nasopharynx, or clivus
a Reproduced with permission from the UICC in Brierley et al4: Brierley
JD, Gospodarowicz MK, Wittekind C. UICC TNM Classification of
Malignant Tumours. 8th ed. Chichester, UK: Wiley-Blackwell; 2017.
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crine carcinomas can be diagnosed with the support of
positive reactivity with at least 1 neuroendocrine marker.
A subset of sinonasal carcinomas appear to be related to
high-risk HPV, including nonkeratinizing squamous cell
carcinoma, basaloid squamous cell carcinoma, papillary
squamous cell carcinoma, adenosquamous carcinoma, and
conventional keratinizing squamous cell carcinoma.64–68
However, the clinical significance of these findings is still
debated, and HPV testing is currently considered investiga-
tional in this context.
CONCLUSIONS
In summary, the contents of the ICCR data set for
reporting carcinomas of the nasal cavity and paranasal
sinuses were reviewed. In such a highly heterogeneous
group of rare tumors, an internationally agreed-upon
pathology data set is important to facilitate data collection
and comparison, ensuring that all clinically relevant
information is included.
The authors would like to express their appreciation to the
sponsoring societies and organizations and give special thanks to
Fleur Webster and Hannah B. Canlas for their exceptional
organizational and editing contributions. The views expressed are
those of the authors solely.
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